SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE
13A-16 OR 15D-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
June, 2024
Commission File Number 1-15182
DR.
REDDY’S LABORATORIES LIMITED
(Translation of registrant’s name into English)
8-2-337, Road No. 3, Banjara Hills
Hyderabad, Telangana 500 034, India
+91-40-49002900
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F x
Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in
paper as permitted by Regulation S-T Rule 101(b)(1): ______
Note: Regulation S-T Rule 101(b)(1) only permits the submission
in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K in
paper as permitted by Regulation S-T Rule 101(b)(7): ______
Note: Regulation S-T Rule 101(b)(7) only permits
the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must
furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the
registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities
are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the
registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other
Commission filing on EDGAR.
Indicate by check mark whether by furnishing the information
contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
Yes
¨
No x
If “Yes” is marked, indicate below the file number assigned
to registrant in connection with Rule 12g3-2(b): 82-________.
EXHIBITS
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
DR. REDDY’S LABORATORIES LIMITED |
|
(Registrant) |
|
|
|
Date: June 05, 2024 |
By: |
/s/ K Randhir Singh |
|
|
Name: |
K Randhir Singh |
|
|
Title: |
Company Secretary |
Exhibit 99.1
June 5, 2024
National Stock Exchange of India Ltd. (Stock Code: DRREDDY-EQ)
BSE Limited (Stock Code: 500124)
New York Stock Exchange Inc. (Stock Code: RDY)
NSE IFSC Ltd. (Stock Code: DRREDDY)
Dear Sir/Madam,
Sub: Disclosure under Regulation 30 of the
SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
This is to inform that ICRA Limited has reaffirmed
the credit ratings assigned to the bank facility of the Company. Please find below the details of revision in ratings of the Company’s
bank facilities:
Details of Bank Limits Rated by ICRA
(Rated on Long-term Scale) |
Amount
(Rs.
crore) |
Rating |
Rating Action |
Fund-based/non-fund-based facilities |
|
|
|
Bank Facilities |
1,200.00 |
[ICRA]AA+ (Stable) |
Reaffirmed |
A copy of the rating rationale issued by ICRA
Limited is enclosed.
This is for your information and record.
Thanking you.
Yours faithfully,
For Dr. Reddy’s Laboratories Limited
K Randhir Singh
Company Secretary, Compliance Officer &
Head-CSR
Encl: As above
|
ICRA Limited |
Ref: ICRA/Dr. Reddy's Laboratories Limited/04062024/1
Date: June 04, 2024
Mr. Ashok Kalyan Tavva
Head – Treasury and Finance transformation,
Dr. Reddy's Laboratories Limited
8-2-337, Road No. 3, Banjara Hills,
Hyderabad – 500 034
Dear Sir,
| Re: | Surveillance of ICRA-assigned Credit Rating for Rs. 500.00 crore Bank Facilities and Enhancement of
Rs. 700.00 Crores Bank Facilities of Dr. Reddy's Laboratories Limited |
Please refer the Rating Agreement/Statement of
Work dated October 25, 2019, executed between ICRA Limited (“ICRA”) and your company, whereby, ICRA is required to review
the ratings assigned to your company, on an annual basis, or as and when the circumstances so warrant. Also, please refer to your Rating
Agreement/Statement of Work dated March 05, 2024 for rating of enhanced captioned limits(s) of Bank Facilities of your company from Rs.
500.00 crore to Rs. 1,200.00 crore.
Please note that the Rating Committee of ICRA,
after due consideration, has reaffirmed the long-term rating at [ICRA]AA+ (pronounced ICRA double A plus) assigned earlier
to the Rs 500.00 crore Bank Facilities of your Company, and has assigned a long-term rating of [ICRA]AA+ (pronounced ICRA double
A plus) to the captioned Bank Facilities of Rs. 700.00 crore (“Rating”). The Outlook on the long-term rating is Stable.
For Rating definition(s), please refer to ICRA website at www.icra.in
In any of your publicity material or other document
wherever you are using the above Rating(s), it should be stated as [ICRA]AA+ (Stable).
The aforesaid Rating(s) will be due for surveillance
any time before May 27, 2025. However, ICRA reserves the right to review and/or, revise the above Rating(s) at any time on the basis
of new information becoming available, or the required information not being available, or other circumstances that ICRA believes could
have an impact on the Rating(s). Therefore, request the lenders and Investors to visit ICRA website at www.icra.in for latest
Rating(s) of the Company.
The Rating(s) are specific to the terms and conditions
of the bank facilities as indicated to us by you, and any change in the terms or size of the same would require a review of the Rating(s)
by us. In case there is any change in the terms and conditions or the size of the rated bank facilities, the same must be brought to our
notice before the bank facilities is used by you. In the event such changes occur after the Rating(s) have been assigned by us and their
use has been confirmed by you, the Rating(s) would be subject to our review, following which there could be a change in the Rating(s)
previously assigned. Notwithstanding the foregoing, any increase in the over-all limit of the bank facilities from that specified in the
first paragraph of this letter would constitute an enhancement that would not be covered by or under the said Rating Agreement.
Building No. 8, 2nd Floor, Tower A |
Tel.: +91.124 .4545300 |
Website: www.icra.in |
DLF Cyber City, Phase II |
CIN : L749999DL1991PLC042749 |
Email: info@icraindia.com |
Gurugram – 122002, Haryana |
|
Helpdesk: +91 9354738909 |
Registered Office: B-710, Statesman House, 148,
Barakhamba Road, New Delhi 110001. Tel. :+91.11.23357940-41
RATING
·
RESEARCH ·
INFORMATION
The Rating(s) assigned must be understood solely
as an opinion and should not be treated, or cause to be treated, as recommendation to buy, sell, or hold the rated [Instrument] availed/issued
by your company.
The Rating(s) assigned to the bank facilities
of your Company shall require revalidation if there is any change in the size of the rated bank facilities.
You are also requested to forthwith inform us
about any default or delay in repayment of interest or principal amount of the instrument rated, as above, or any other debt instruments/
borrowing and keep us informed of any other developments which may have a direct or indirect impact on the debt servicing capability of
the company including any proposal for re-schedulement or postponement of the repayment programmes of the dues/ debts of the company with
any lender(s) / investor(s). Further, you are requested to inform us immediately as and when the borrowing limit for the instrument rated,
as above, or as prescribed by the regulatory authority(ies) is exceeded.
We look forward to your communication and assure
you of our best services.
With kind regards,
Yours sincerely,
For ICRA Limited
Srikumar Krishnamurthy
Senior Vice President and Co-Group Head
ksrikumar@icraindia.com
Appendix –A
Instrument Details
Details of Bank Limits Rated by ICRA (Rated on
Long-term Scale) |
Amount (Rs. crore) |
Rating |
Rating Assigned on |
Fund-based/non-fund-based facilities |
|
[ICRA]AA+ (Stable) |
May 28, 2024 |
Citibank |
1,200.00 |
Total |
1,200.00 |
|
|
Dr Reddys Laboratories (NYSE:RDY)
過去 株価チャート
から 5 2024 まで 6 2024
Dr Reddys Laboratories (NYSE:RDY)
過去 株価チャート
から 6 2023 まで 6 2024